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Peptidoglycan (PGN) recognition proteins (PGLYRPs) are a highly conserved group of
host defense proteins in insects and mammals that sense bacterial cell wall PGN and act
bactericidally or cleave PGN by amidase function. Streptococcus (S.) pneumoniae is one
of the top five killers worldwide and causes, e.g., pneumonia, endocarditis, meningitis
and sepsis. S. pneumoniae accounts for approximately 1.5–2 million deaths every year.
The risk of antibiotic resistance and a general poor prognosis in young children and
elderly people have led to the need for new treatment approaches. To the best of
our knowledge, there is no report on the relevance of PGLYRP2 in lung infections.
Therefore, we infected mice deficient for PGLYRP2 transnasally with S. pneumoniae
and examined the innate immune response in comparison to WT animals. As expected,
PGLYRP2-KO animals had to be sacrificed earlier than their WT counterparts, and this
was due to higher bacteremia. The higher bacterial load in the PGLYRP2-KO mice was
accomplished with lower amounts of proinflammatory cytokines in the lungs. This led
to an abolished recruitment of neutrophils into the lungs, the spread of bacteria and the
subsequent aggravated course of the disease and early mortality of the PGLYRP2-KO
mice. These data suggest a substantial role of PGLYRP2 in the early defense against
S. pneumoniae infection, and PGLYRP2 might also affect other infections in the lungs.
Keywords: infectious diseases, innate immunity, mouse, PGRP, PGLYRP2, pneumonia, S. pneumoniae
INTRODUCTION
Pneumonia is a common infectious disease divided into several environmental classes, including
hospital-associated pneumonia (hospital-acquired pneumonia, ventilator-associated pneumonia,
healthcare-associated pneumonia) and community-acquired pneumonia (CAP). Whereas hospital-
associated pneumonia occurs during or after hospitalization or treatment of generally sick and/or
immunosuppressed patients, CAP occurs outside the hospital in all kinds of people (Anand and
Kollef, 2009). Therefore, the common pathogens and the course of pneumonia differ in these
groups. In CAP, there is a u-shaped curve of mortality with the highest rates in individuals below 5
and higher than 65 years of age and a very low overall mortality (below 1% of all cases) (Mandell,
2015; Prina et al., 2015). Nevertheless, CAP is one of the main causes of death worldwide, and in
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patients who need to be hospitalized, short-term mortality of
up to 50% with an estimated overall mortality of approximately
14% is reported (Mandell, 2015; Prina et al., 2015). In up to
50% of all cases of CAP, Streptococcus (S.) pneumoniae—also
called pneumococcus—is the main causative pathogen for this
disease, which costs approximately 1.5–2 million lives every year
(Höffken et al., 2010; Dockrell et al., 2012; Troeger et al., 2017).
S. pneumoniae is a gram-positive diplococcus that resides
asymptomatically in the nasopharynx of many healthy
individuals. In susceptible individuals, S. pneumoniae cannot
only lead to pneumonia but also spread from the respiratory
tract into the blood and distal organs and can cause, e.g.,
sepsis, meningitis, rhinitis, sinusitis, and endocarditis (Bhatty
et al., 2011; Geno et al., 2015). Currently, 97 different serotypes
of pneumococci are known, characterized by their different
polysaccharide capsules (Geno et al., 2015). The capsule is, on the
one hand, a major virulence factor that protects pneumococcal
cell wall components, such as peptidoglycan (PGN) and (lipo-)
teichoic acids, from recognition by the immune system via
pattern recognition receptors (PRRs) or the complement system
and degraded by host defense molecules (HDMs) (Geno et al.,
2015). On the other hand, the capsule can hinder bacteria, e.g.,
from traversing the epithelial barrier and entering the blood
stream (Hammerschmidt et al., 2005).
Peptidoglycan recognition proteins (PGRPs) are a class of
HDMs that were first described in 1996 independently by
two groups. Yoshida et al. (1996). isolated a PGRP from the
silkworm (Bombyx mori). Kustikova et al. (1996) found the
tag7 protein (also known as PGRP-S or PGLYRP1) in mice.
In insects, there is a wide variety of different PGRPs. The
anopheles or the drosophila for example have 9 and more than
19 different proteins/splice variants of this group, respectively.
However, in mammals there are only four known proteins
and named as PGLYRP1 through PGLYRP4 (Kurata, 2014;
Dziarski and Gupta, 2018).
For human PGLYRPs 1, 3, and 4, a direct bacteriostatic
or bactericidal effect has been shown for more than a decade
(Lu et al., 2006), but PGLYRP2 was mostly considered to
function as an amidase by hydrolyzing bacterial cell wall
PGN (Gelius et al., 2003; Wang et al., 2003). Additionally,
the influences of PGLYRP2 on innate immune signaling have
been discussed, as PGLYRP2 might change the recognition of
PGN via NOD1/NOD2 receptors by degradation (Chaput et al.,
2013). Recently, reports have shown direct antibacterial functions
for PGLYRP2 (Bobrovsky et al., 2016; Torrens et al., 2017).
Furthermore, PGLYRPs play a role in the maintenance of normal
microbiota (Saha et al., 2010). Gene knockouts for one of the
four genes lead to a more proinflammatory phenotype of the
microbiome, which could lead to more severe disease outcomes
(Saha et al., 2010; Dziarski et al., 2016).
Other functions of PGLYRPs include anti-tumor and
chemotactic activities for PGLYRP1 (Dukhanina et al., 2015;
Sharapova et al., 2017a,b), modulation of phagocytosis and
cytokine release for PGLYRP3 (Zenhom et al., 2011; De Marzi
et al., 2015) and regulation of the Treg/Th17 balance for
PGLYRP4 (Park et al., 2011b). The different abilities to function
as an antibacterial substance or an amidase or immune sensor,
are likely due to different binding sites and a highly variable
N-terminal region of the protein structure (Guan et al., 2005).
PGLYRPs have two different binding sites, which are opposite
of each other. First, there is a PGN binding site, which binds
degradation products of PGN, and second, there is an alternative
binding site, which may function as a mediator of immune
receptors (Guan et al., 2005).
These functions might lead to different regulatory
mechanisms, which could have opposing effects for gene
knockouts of different PGLYRPs in a single disease or in the
knockout of a single PGLYRP in different diseases. For example,
when infecting the murine cornea with Pseudomonas aeruginosa
to induce corneal keratitis, it was illustrated that PGLYRP2-KO
mice had better clearance and lower clinical scores (Gowda
et al., 2015). Furthermore, these mice were nearly fully protected
against PGN- or muramyl dipeptide (MDP)-induced arthritis
(Saha et al., 2009). On the other hand, PGLYRP2-KO mice
are more susceptible to chemically induced psoriasis-like skin
inflammation (Park et al., 2011a) or DSS-induced colitis (Saha
et al., 2010). However, reports of activity against pneumococci
are rare. There is only one report for PGLYRP3 (Shrivastav et al.,
2018), showing no effect on S. pneumoniae lung infection in
mice. Furthermore, unpublished observations by our group show
indirect immunomodulatory effects by PGLYRP4 in the same
experimental setting.
Understanding the mechanisms of endogenous HDMs could
lead to new and innovative options to treat antibiotic-resistant
microbes. Therefore, we aimed to elucidate the influences of
PGLYRP2 in pneumococcal pneumonia. This disease is a major
cause of death, especially in people with lower functioning
immune systems, such as young children and elderly people.
Here, to the best of our knowledge, we are the first to report
the direct impact of the PGLYRP2 gene knockout on bacterial
lung infection and to illustrate that PGLYRP2 is important
for host defense. We further analyzed changes in the innate
immune system and demonstrated important new insights into




Prof. Dr. Roman Dziarski (Department of Microbiology and
Immunology, Indiana University School of Medicine, Indiana,
United States) kindly provided the breeding pairs for the
PGLYRP2-KO and WT mice. Animals were generated as
described before on a BALB/c background (Saha et al., 2009).
Mice were bred and housed at the central breeding facility of
the Charité–Universitätsmedizin Berlin (Forschungseinrichtung
für Experimentelle Medizin, FEM) under specific pathogen-free
conditions. All experimental procedures were in compliance
with the Federation of European Laboratory Animal Science
Associations (FELASA) guidelines and recommendations for
the care and use of laboratory animals, as well as approved
by local institutional (Charité-Universitätsmedizin Berlin) and
governmental (Landesamt für Gesundheit und Soziales Berlin,
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approval ID: G0220/13) authorities. Animals were housed at a
12 h light/dark cycle, with food and water ad libitum. In all
experiments, the mice were anesthetized intraperitoneally (i.p.)
with ketamine and xylazine, and their suffering was minimized in
compliance with the 3R principles.
Genotyping
Mice were routinely analyzed for the genotype as described
previously (Saha et al., 2009; Shrivastav et al., 2018). Briefly,
tail tips were digested overnight in Tris-EDTA-SDS buffer and
Proteinase K (Sigma-Aldrich, St. Louis, MO, United States).
DNA was isolated to perform PCR with the following primers:
GCTGCGCAATTCGCGCAGGTCTC (WT, forward) and ATGG
TTCCATCAGCAAAGTGCTGG (WT, reverse); TGCGAGGCC
AGAGGCCACTTGTGTAGC (PGLYRP2, forward) and
ATGGTTCCATCAGCAAAGTGCTGG (PGLYRP2, reverse).
DreamTaq DNA Polymerase was used according to the
manufacturer’s instructions (Life Technologies GmbH;
Darmstadt; Germany). PCR products were run on an agarose
gel, and DNA bands were visualized with ethidium bromide
under UV light.
Bacteria
We used the S. pneumoniae WT serotype 3 strain A66
(NCTC 7978) for all experiments. Streptococci were grown on
Columbia agar with 5% sheep blood (BD Biosciences, Heidelberg,
Germany) overnight (37◦C, 5% CO2). Single colonies were
picked and inoculated in Todd-Hewitt broth + 0.5% yeast (both
BD Biosciences) supplemented with 10% FCS. Bacteria were
grown until the mid-log phase (OD600: 0.3-0.4, 37◦C, 5% CO2),
centrifuged (2,000 × g, 10 min) and resuspended in cell culture
media (in vitro stimulation of cells) or sterile PBS (in vivo
infection) at the appropriate concentration.
Mouse Infection Model
Female BALB/c WT or BALB/c PGLYRP2-KO mice (8-12 weeks)
were anesthetized by i.p. injection of ketamine and xylazine
(both Rotexmedica, Luitré, France) and inoculated transnasally
with 20 µl of bacterial suspension of S. pneumoniae or 20 µl
of sterile PBS as a control. In total, 98 mice were used in this
study: 22 mice for bacterial load (11 mice per group), 49 mice
for approximate survival (25 WT and 24 PGLYRP2-KO mice)
and 27 mice for cell recruitment and cytokine measurements
(each 6 uninfected WT and PGLYRP2-KO, 8 infected WT and
7 infected PGLYRP2-KO mice). Mice were monitored before
infection and every 12 h thereafter to assess clinical signs of
illness (blowsy fur, crusty secretion on the eye rim, reduced
reaction or movement, isolation, temperature ≤ 35.0◦C, body
weight loss, accelerated or cumbersome breathing, pain, paleness,
staggering). For the evaluation of the approximate survival after
pneumococcal infection, disease severity was monitored for 10
days. Mice were euthanized by cervical dislocation after i.p.
injection of ketamine and xylazine when they reached at least
one of the predefined humane endpoints or at the end of the 10
days period. Humane endpoints were defined as (i) body weight
loss ≥ 25%, (ii) cumbersome breathing, and (iii) accelerated
breathing in combination with staggering or pain.
Bacterial Load
Lung and spleen homogenates or EDTA blood was plated on
Columbia agar with 5% sheep blood in serial dilutions. After
overnight incubation at 37◦C with 5% CO2, the colonies were
counted manually, and the CFUs were calculated.
Cell Isolation
Primary cells from untreated WT mice were isolated after
anesthesia with ketamine and xylazine and exsanguination by
opening the vena cava caudalis. In the case of alveolar epithelial
cells, heparin (Rotexmedica) was included in the anesthesia mix.
Alveolar Macrophages (AMs)
AMs were isolated as described earlier (Cakarova et al., 2009).
Briefly, the lungs were lavaged (2 mM EDTA in PBS, 5 ml),
and the cell suspension centrifuged (300 × g, 10 min, 4◦C).
Afterward, the cells were suspended in RPMI1640 (10% FCS, 1%
Glu, 1% P/S) and seeded in cell culture plates. The medium was
exchanged 2 h later to remove non-adherent cells. Cell purity and
morphology was routinely checked by light microscopy. The next
day, the medium was changed to RPMI1640 (2% FCS, 1% Glu) 2 h
before infection.
Alveolar Epithelial Cells (AECs)
AECs were harvested from perfused and digested lungs (5,000
U dispase) as described previously (Cakarova et al., 2009)
with some modifications as follows: after generation of the
single cell suspension by passing macerated lungs through
different cell strainers (100, 70, and 30 µm), the suspension
was centrifuged (200 × g, 10 min) and resuspended in
PBS containing 3% FCS and 10 mM EDTA. Unwanted cells
were depleted by the addition of biotinylated anti-CD45,
anti-CD16/CD32, anti-CD31 antibodies (BD Biosciences) and
MagniSort Streptavidin Negative Selection Beads (eBioscience,
Frankfurt am Main, Germany). Then, cells were seeded in
DMEM (10% FCS, 1% Glu, 1% P/S) in cell culture plates
and incubated (37◦C, 5% CO2, overnight). Cell morphology
was routinely checked by light microscopy. In addition, FACS
staining was performed for cell purity and was always above
90% (see also Cakarova et al., 2009). Two hours before the
experiment, the medium was changed to DMEM containing 2%
FCS and 1% Glu.
Bone Marrow Derived Neutrophils (PMNs)
For isolating PMNs, the femurs and tibiae of mice were
flushed with PBS, and cells were filtered through a 70 µm cell
strainer as described earlier (Shrivastav et al., 2018). PMNs were
then positively isolated using the mouse anti-Ly6G MicroBead
kit (Milteny Biotec GmbH, Telterow, Germany) according to
manufacturer’s instruction, seeded in RPMI1640 containing 2%
FCS and 1% Glu and infected immediately. This cell isolation
method is considered to provide highly pure and viable cells
(Swamydas et al., 2015). Furthermore, the positive selected PMNs
can strongly induced proinflammatory cytokines (as assed by
ELISA, data not shown), indicating that these cells have not lost
their capacity to respond to bacteria.
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Gene Expression Analysis
Analysis of the gene expression of Pglyrp2 was performed in
isolated primary BALB/c WT AECs, AMs, and PMNs that were
stimulated for 6 h with S. pneumoniae. RNA was extracted
from the cells using TRIzol (Thermo Fisher Scientific, Schwerte,
Germany) according to the manufacturer’s instructions. Total
RNA (1 µg) was used to transcribe cDNA (High-Capacity cDNA
Reverse Transcription Kit; Life Technologies GmbH). Samples
were preamplified for 18 cycles (TaqManPreAmp Master Mix Kit;
Life Technologies GmbH) and used for TaqMan R© quantitative
gene expression analysis using specific primers (Taqman
assay sequence numbers: Gapdh Mm99999915_g1, Pglyrp2
Mm01348077_m1; both Life Technologies GmbH). Quantitative
real-time PCR was performed according to the manufacturer’s
instructions using the following cycling conditions: 2 min, 50◦C;
10 min, 95◦C and 40 cycles with 15 s, 95◦C and 1 min, 60◦C. The
efficiency-corrected 11CT method was used for the calculation
of the relative expression (Pfaﬄ, 2001). Gapdh was used as a
housekeeping gene, and uninfected WT cells were used as an
untreated control.
Cytokine Measurement
Mice infected with S. pneumoniae were sacrificed 48 h post-
infection (hpi), and the lungs were taken and homogenized
in HBSS with a protease inhibitor (Complete R© Mini, Roche,
Mannheim, Germany) in a FastPrep-24 (MP Biomedicals,
Eschwege, Germany). The homogenate was centrifuged at
14,000 × g for 10 min, and the supernatant was analyzed
by a mouse multiplex ELISA according to the manufacturer’s
instructions (Procartaplex, eBiosience).
Cell Recruitment
Lungs from mice infected with S. pneumoniae or PBS-instilled
control mice were processed according to Shrivastav et al. (2018).
Briefly, lungs were perfused via the heart with HBSS, minced in
RPMI1640 with 10% FCS and digested with Collagenase A and
DNase I (both Roche) at 37◦C for 1 h. A single cell suspension was
generated, washed with HBSS and blocked with mouse serum.
Differentially conjugated monoclonal antibodies against the
following markers, as well as the appropriate isotype controls,
were used for surface staining: CD3e, CD4, CD8a, CD11b,
CD11c, CD19, CD45, CD49b, F4/80, TCR-γδ, GR1, I-A/I-E,
CD64, and SiglecF (BioLegend, Aachen, Germany). Cells were
washed with HBSS, fixed with 2% PFA (Merck, Darmstadt,
Germany), washed again, suspended in HBSS and kept at 4◦C
until measurement. Flow cytometry was performed on a FACS
ARIA III flow cytometer (BD Biosciences), with 100,000 events
per sample at a minimum.
Neutrophils were identified as CD45+, GR1high, CD11bhigh,
AMs as CD45+, CD11chigh, SiglecFhigh and dendritic cells (DCs)
as CD45+, CD11chigh, SiglecF−/low, CD49b−, MHC IIhigh/int.
Classical B cells were identified as CD45+, CD3−, CD49b−,
CD19+, whereas classical T cell populations were divided into T
helper cells (CD45+, CD3+, CD4+, CD8−) and cytotoxic T cells
(CD45+, CD3+, CD8+, CD4−). Furthermore, we stained for the
two major innate lymphocyte subsets γδ T cells (CD45+, CD3+,
CD4−, CD8−, TCR-γδ+) and NK cells (CD45+, CD3+, CD49b+,
CD19−). The classical NK cell marker NK1.1 is not expressed in
BALB/c mice. Therefore, we used the pan-NK cell marker CD49b
(Hackstein et al., 2012).
Data Analysis
Analysis of flow cytometry data was performed using FlowJo v10
(FlowJo, LLC, Ashland, OR, United States). Statistical analysis
was performed using Prism 6 (GraphPad software, La Jolla, CA,
United States). Samples were categorized by optical analysis and
Shapiro-Wilkinson normality test (threshold at p = 0.05) to one
of the following distributions: (A) Gaussian, (B) log-normal, (C)
other non-Gaussian. Statistical significance (p ≤ 0.05) was then
analyzed by appropriate tests as stated in the respective figure
legends. Differences in survival were analyzed by the Gehan-
Breslow-Wilcoxon test. Significance is indicated with asterisks (∗)
if p ≤ 0.05. The exact p-values are provided if p < 0.1, but >0.05
and the results are considered not significant if p ≥ 0.1.
RESULTS
Gene Expression of Pglyrp2 Was Induced
in Bone Marrow-Derived Neutrophils and
Macrophages
There is little knowledge about the expression of PGLYRPs in
lungs. Only single reports showed expression of PGLYRP1 in
mouse lungs at the mRNA and protein levels (Yao et al., 2013) or
Pglyrp3 and Pglyrp4 in mouse lungs at the mRNA level (Mathur
et al., 2004). Furthermore, we recently showed that Pglyrp3 is
expressed in AMs, AECs, and PMNs (Shrivastav et al., 2018).
Because we are especially interested in resident and recruited
cells sensing or fighting S. pneumoniae in the lungs, we started
our examinations by analyzing the expression of Pglyrp2 in
uninfected and infected isolates of primary BALB/c WT cells. We
chose to analyze AECs, AMs, and PMNs because these cells are
either the first cells to recognize invading pathogens (AECs and
AMs) or are the major cell type for clearance of S. pneumoniae
(PMNs) (Kolaczkowska and Kubes, 2013; Hallstrand et al., 2014).
Pglyrp2 mRNA was detectable at very low levels in PMNs,
AMs and AECs. In vitro infection of these primary cells with
S. pneumoniae significantly induced Pglyrp2 expression in AECs
by twofold and by approximately 850-fold in AMs but did not
alter the expression in PMNs (Figure 1).
PGLYRP2-KO Mice Show an Aggravated
Course of Bacterial Pneumonia
Compared to WT Mice
Deletion of PGLYRP2 might lead to an altered immune response
to pathogens due to differences in the sensing of PGNs or direct
antibacterial activity. Therefore, we first analyzed the course
and severity of pneumococcal pneumonia with an approximate
survival analysis. After infection, WT and PGLYRP2-KO mice
showed clinical manifestation of the infection in a mean of 2
days (Figure 2A). While the first occurrence of clinical signs
was visible 1 day after infection, most animals were euthanized
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FIGURE 1 | Enhanced gene expression of Pglyrp2 in isolated primary BALB/c
WT cells induced by S. pneumoniae. Alveolar epithelial cells (AECs), alveolar
macrophages (AMs) and bone marrow-derived neutrophils (PMNs) were
infected for 6 h with S. pneumoniae (A66) to analyze the mRNA expression of
Pglyrp2 by qPCR. Relative expression was calculated by the 11CT method
with Gapdh as the housekeeping gene and uninfected WT cells as the control.
Three (AECs, PMNs) or four (AMs) independent experiments (mean + SEM).
The dotted line represents the level of untreated control. Statistics: Student’s
t-test on logarithmic data. ∗∗p ≤ 0.01, ns, not significant.
according to the predefined endpoints or recovered after 5–6
days (Figure 2B). The course of clinical apparent pneumonia
was significantly different in the WT vs. PGLYRP2-KO mice
(p < 0.0001, Figure 2B). The first mice reached the predefined
humane endpoints for euthanasia 3 days after infection and
there were significant differences in the approximate survival
between days 3.5 and 5 in the PGLYRP2-KO vs. WT mice, but
not at the end of the experiment (Figure 2C). Nevertheless, there
was a significant difference in the time when mice had to be
sacrificed in the PGLYRP2-KO and WT mice (Figure 2D). The
PGLYRP2-KO mice had to be euthanized at a median of 1.5
days earlier (median: 3.5 days, interquartile range (IQR): 3.25-
4.0) than WT animals (median: 5.0 days, IQR: 4.0-5.5). The
faster progression of pneumococcal disease in the PGLYRP2-
KO animals is not only represented by the approximate survival
curve but also by the clinical score. The PGLYRP2-KO mice
showed significantly higher clinical scores compared to the WT
mice at 3 days and higher scores 3.5 days p.i., whereas the WT
mice showed elevated clinical scores for a longer period of time
(Supplementary Figures S1A,B).
PGLYRP2-KO Mice Have a Higher
Susceptibility for Bacterial Spread Into
the Periphery
Next, we wanted to investigate whether PGLYRP2 deficiency
leads to an altered restriction of bacterial growth upon infection
with S. pneumoniae. We chose the time when mice first showed
clinical signs of illness and analyzed the bacterial burden in
the lungs, spleens and blood. While there was no difference
in the bacterial burden in lungs (Figure 3A), there were
significantly more bacteria in the spleens (Figure 3B) and a trend
toward higher bacterial burden in the blood (Figure 3C) in the
PGLYRP2-KO compared to the WT mice.
Lower Amounts of Neutrophil Attracting
KC and Proinflammatory Cytokines Were
Detected in Lungs of the Infected
PGLYRP2-KO Than the WT Mice
To check if there was a lower proinflammatory response in
the PGLYRP2-KO mice, the in vivo cytokine response to
S. pneumoniae infection in the lungs was analyzed 48 hpi.
Indeed, there was less of the proinflammatory and neutrophil
attracting chemokine KC (a mouse homolog to human
IL-8) (Figure 4A) and significantly less proinflammatory IL-6
(Figure 4B) detectable in the lung homogenates of PGLYRP2-
KO compared to WT mice. In addition, we observed lower
amounts of IFN-γ and TNF-α (Figures 4C,D) in PGLYRP2-KO
mice. In conclusion, there is a reduction in cytokine level in
lungs from infected PGLYRP2-KO vs. WT mice although there
were no significant differences in the bacterial load at this time
point (Figure 3A).
Lower Number of Neutrophils Were
Recruited to the Site of Infection 48 hpi
Because alterations in the cytokine profile can change immune
responses, e.g., cell recruitment, we analyzed the lungs of
infected and uninfected animals 48 hpi for the proportion
of different immune cells. Strikingly, we could not detect a
recruitment of neutrophils into the lungs of the PGLYRP2-
KO animals 48 hpi, whereas WT animals significantly recruited
neutrophils into the lungs (Figure 5). However, no effects
were seen on the total leukocyte count (Supplementary
Figure S2A) or in other major innate cell populations such
as AMs (Supplementary Figure S2B), DCs (Supplementary
Figure S2C), γδ T cells (Supplementary Figure S2D) and NK
cells (Supplementary Figure S2E). B cells were reduced in
infected WT and PGLYRP2-KO mice compared to the PBS-
treated mice, but no difference could be detected between the
WT and PGLYRP2-KO mice (Supplementary Figure S2F).
The PGLYRP2-KO mice had lower basal levels of Tc cells
(Supplementary Figure S2G), but their Th cells (Supplementary
Figure S2H) did not show any difference at 48 hpi in the
infectious state.
DISCUSSION
Host defense molecules have a major impact on the defense
of invading microorganisms. They can act through direct and
indirect mechanisms such as direct killing or arresting of
growth and replication or by activating innate and adaptive
immune cells to let them sense, kill and clear the unwanted
microorganisms (Hancock et al., 2016). If these mechanisms
are altered or not fully mature, invading pathogens such
as S. pneumoniae can evade sensing and killing and lead
to severe life-threatening diseases. We commonly treat such
bacterial infections with antibiotics, but, e.g., emerging resistance
makes treatment difficult and too often inefficient (José et al.,
2015; Spellberg et al., 2015). Understanding the mechanisms
of endogenous HDMs could lead to new approaches to cure
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FIGURE 2 | Earlier death of PGLYRP2-KO mice in a 10-day approximate survival analysis of infected mice. PGLYRP2-KO and WT mice were infected with
S. pneumoniae (A66, 5 × 104 CFU). Clinical signs and survival were recorded for a period of 10 days every 12 h (WT: n = 25, PGLYRP2-KO: n = 24; five independent
experiments). (A) The day the first clinical signs were observed is given as the median ± 95% CI and (B) the number of sick animals is expressed as total numbers
without dead animals. Dots represent the number of sick animals, and bands represent the 95% CI of a log-Gaussian curve fit. The number of animals that showed
clinical signs of sickness and are therefore included in this analysis are n = 17 for WT and n = 20 for PGLYRP2-KO. (C) Survival is shown as the Kaplan-Mayer curve,
and (D) the day of death was assessed by excluding all surviving animals and calculating the median and 95% confidence interval from the deceased animals (WT:
n = 11, PGLYRP2-KO: n = 13). Statistics: (A,D) Mann–Whitney U-test and (B) log-Gaussian fit, (C) Gehan-Breslow-Wilcoxon test. #p ≤ 0.1, ∗p ≤ 0.05, ∗∗p ≤ 0.01,
ns, not significant.
FIGURE 3 | Higher bacterial burden in the spleen of the PGLYRP2-KO vs. WT mice. Bacterial burden was determined in the (A) lung, (B) spleen, and (C) blood of
S. pneumoniae-infected (A66, 105 CFU) animals 48 hpi. The results are from 11 animals per group in three independent experiments. Colony counts are expressed
as the mean ± SEM. The dotted line represents the lower limit of detection. Undetected samples were set to half of the LLOD for statistical purposes. Statistics:
Student’s t-test on logarithmic data. ∗∗p ≤ 0.01, ns, not significant.
life-threatening diseases. All four mammalian PGLYRPs are
known for their antibacterial functions (Lu et al., 2006; Wang
et al., 2007; Bobrovsky et al., 2016; Torrens et al., 2017),
and PGLYRPs 1 and 3 were shown to also have immune
modulatory functions (Zenhom et al., 2011; De Marzi et al., 2015;
Sharapova et al., 2017b).
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FIGURE 4 | Impaired cytokine secretion in whole lung homogenates of PGLYRP2-KO mice. Mice were infected with S. pneumoniae (A66, 105 CFU) for 48 h. (A) KC,
(B) IL-6, (C) IFN-γ, and (D) TNF-α were measured by multiplex ELISA. Sample size: WT and PGLYRP2-KO PBS: n = 6 each, WT infected: n = 8, PGLYRP2-KO
infected: n = 7. Data are represented by the means + SEMs. Thresholds for nondetection were set to the half of the lower limit of detection for statistical purposes.
Statistics: ordinary one-way ANOVA with Holm-Sidak’s correction for multiple comparisons on logarithmic data. ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001,
∗∗∗∗p ≤ 0.0001, ns: not significant.
FIGURE 5 | Reduced recruitment of neutrophils into the lungs of
PGLYRP2-KO mice 48 hpi. Recruitment of PMNs into the lungs was analyzed
by flow cytometry in PBS and S. pneumoniae-infected animals 48 hpi (A66,
105 CFU). Means ± SEMs of six (WT PBS and PGLYRP2-KO PBS), seven
(PGLYRP2-KO infected) or eight (WT infected) mice. Statistics: ordinary
one-way ANOVA with Holm-Sidak’s correction for multiple comparisons.
∗p ≤ 0.05, ∗∗p ≤ 0.01, ns, not significant.
To fulfill these important functions, HDMs need to be
expressed in the same areas where pathogens and commensals
reside or they need to be transported to these locations. It is
known that PGLYRPs 3 and 4 are expressed, e.g., in epithelial
cells from the gut to the skin, and the eye to the lungs (Liu et al.,
2001; Mathur et al., 2004; Uehara et al., 2007; Gowda et al., 2015;
Hua et al., 2015; Shrivastav et al., 2018). PGLYRP1 is mainly
expressed and stored in the granules of PMNs and may therefore
act directly on pathogens or on cells in the proximity of pathogens
after degranulation of the PMNs (Liu et al., 2000). Nevertheless,
PGLYRP1 is also expressed in diverse epithelial cells and in
macrophages in the lung (Yao et al., 2013). The fourth member
of this class of HDMs, PGLYRP2, is mainly expressed in the liver
and secreted into the blood (Xu et al., 2004). Its expression was
also determined, e.g., in the intestine (Duerr et al., 2011; Lee et al.,
2012), in keratinocytes (Wang et al., 2005), in the brain (Arentsen
et al., 2017), as well as in the lungs of monkeys (Maniar-Hew
et al., 2013). Own unpublished observations in C57BL/6 mice
indicated, that the expression of Pglyrp2 is decreased in whole
lung tissue during pneumococcal infection. However, so far, it is
unknown which cells in the lung express PGLYRP2. We showed
here for the first time that AECs and AMs express Pglyrp2
and that this expression is upregulated in both cell types upon
infection with S. pneumoniae. This is contrary to our previous
unpublished observations in C57BL/6 mice, but indicate, that
there might be different expression patterns ins different mouse
modes, in vivo and in vitro infection, or due to blood cells, which
were still in the lung during RNA isolation. AECs and AMs are
the first cells to come in close contact with invading pathogens in
the lower respiratory tract and these cells are important for, e.g.,
the establishment of the barrier function and the recruitment and
activation of PMNs (Kolaczkowska and Kubes, 2013; Hallstrand
et al., 2014). This led us to hypothesize that there might be a
difference in the local lung environment leading to a change in
bacterial clearance.
Therefore, we analyzed the bacterial burden of infected
animals and found no differences in lungs of PGLYRP2-KO and
WT mice. In contrast, there were significantly more bacteria in
the spleens of the PGLYRP2-KO vs. WT mice and the PGLYRP2-
KO mice also tended to have more bacteria in their blood.
Therefore, it seemed that bacteria can more easily disseminate
into the periphery of the PGLYRP2-KO mice. A greater spread of
bacteria can be accompanied by a reduced control of immunity
by lower levels of proinflammatory cytokine release in the
lungs and lower recruitment of e.g., phagocytic immune cells.
This phenotype was already described for the PGLYRP2-KO
mice in a MDP-induced arthritis model. The authors showed
a reduced production of local proinflammatory cytokines and
a reduced recruitment of PMNs into the hind limbs of the
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PGLYRP2-KO vs. WT mice (Saha et al., 2009). Therefore,
we analyzed the local proinflammatory cytokine response and
could indeed show lower amounts of KC, IL-6 and TNF-α.
KC especially is strongly associated with the recruitment of
neutrophils but TNF-α is also known to have functions in
adherence and trafficking of PMNs (Kolaczkowska and Kubes,
2013; Rossaint and Zarbock, 2013). IFN-γ and IL-6, however,
have no chemotactic effects (Borish et al., 1989; Ellis and Beaman,
2004), but they are important for the activation of PMNs (Borish
et al., 1989; Ellis and Beaman, 2004; Kolaczkowska and Kubes,
2013; Rossaint and Zarbock, 2013).
Thus far, the mechanism behind this reduced cytokine
response is still unclear. One possibility is an alteration of
S. pneumoniae PGN detection. However, Saha et al. (2009)
reported that the effects of PGLYRP2 on MDP-induced arthritis
is independent of the amidase activity. Another mechanism could
be an influence on the NF-κB pathway. Zenhom et al. described
a regulation of IκBα by PGLYRP3. Other mechanisms could be
imagined and should be addressed in the future.
Because of this reduced proinflammatory local cytokine
response, we analyzed the cell populations in the lungs of
uninfected and infected WT and PGLYRP2-KO mice for changes.
Strikingly, we found fewer neutrophils in the lungs of infected
PGLYRP2-KO compared to WT mice at 48 hpi. In fact, there
was not only a reduction in PGLYRP2-KO mice but also a nearly
abolished recruitment at this time compared to PBS-treated mice.
This impaired immune response led to a worsened early control
of bacterial spread and to a faster progression of the disease.
In our approximate survival analysis, we had to euthanize
the PGLYRP2-KO mice 1.5 days earlier than the WT mice.
This earlier euthanization was also correlated with higher
clinical scores at earlier times in the PGLYRP2-KO mice. In
contrast, there were no differences in the onset of clinical
signs or the overall approximate survival in these experiments.
However, one could imagine that a deficiency in Pglyrp2 gene
expression or function, e.g., a loss-of-function mutation by
single nucleotide polymorphism (SNPs), could lead to higher
mortality or worsened progression of pneumonia in humans
because there would be less time for the treatment of ill patients.
Unfortunately, there is little knowledge about SNPs in Pglyrp2.
Only two reports suggested associations between SNPs in Pglyrp2
and Parkinson’s disease (Goldman et al., 2014) or Crohn’s disease
(Zulfiqar et al., 2013).
Still unresolved is why there was no difference in the overall
approximate survival between the WT and PGLYRP2-KO
mice. There are several possibilities that might explain
these circumstances. First, neutrophil recruitment could be
delayed instead of being completely abolished. Therefore, later
recruitment would lead to the rescue of animals at later times.
Second, neutrophil recruitment could be only impaired in the
lungs. Recruitment into the blood might be different from what
we see in the lungs. Third, the adaptive immune system might be
unaffected by PGLYRP2 deficiency, and therefore neutralizing
antibodies might rescue animals at approximately day 4–5. In
addition, there might be several other mechanisms.
Taken together, we used the PGLYRP2-KO mouse model to
analyze the function of this HDM in pneumococcal pneumonia.
Deficiency of this particular gene led to early mortality of infected
animals by an abolished neutrophil recruitment and increased
spread of bacteria into the periphery. Nevertheless, animals,
which survived the first 3–4 days, recovered from the infection.
This is possibly mediated by protective, unaffected adaptive
immune responses. However, we have no proof, so far, for this
hypothesis. It is known that HDMs do not need to show direct
antibacterial activity against a pathogen to affect the course of
a disease (Hancock et al., 2016). Activation and modulation of
major compartments of the innate immune system by those
HDMs such as PGLYRP2 are alternative mechanisms to protect
against diseases. Taking into account that neutrophils are the
most necessary cell type to clear an infection and that their
recruitment is impaired by a deficiency in PGLYRP2, one could
imagine that polymorphisms in this gene could be directly linked
to a higher susceptibility to pneumococcal pneumonia as well
as other lung infections. Further studies should be conducted
to decipher alterations of the immune system by PGLYRPs and
possible implications for clinical usage.
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